Stock Alert: Immuron Jumps 51% On Research Deal With Australia's CSIRO

(RTTNews) - Shares of Australian biopharma company Immuron Ltd. (IMRN) are gaining more than 51 percent or $4.00 in Friday's morning trade at $11.75.

Friday, Immuron said it has executed a research agreement with Australia's national science agency, CSIRO, to produce a new oral therapeutic against Campylobacter and Entero-Toxigenic Escherichia coli or ETEC for clinical evaluation by the US Department of Defense. Under the terms of the deal, CSIRO has been engaged to produce a hyper-immune bovine colostrum product using vaccines developed by the Naval Medical Research Center or NMRC. The stock has traded in a range of $1.55 to $28.99 in the past 52 weeks.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


More Related Articles

Sign up for Smart Investing to get the latest news, strategies and tips to help you invest smarter.